Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
bevacizumab (avastin) (1 trial)
cyt002-nicqb (1 trial)
everolimus (zortress) (1 trial)
paclitaxel (taxol) (1 trial)
rituximab (rituxan) (1 trial)
Carcinoma, Hepatocellular (Phase 2)
Leukemia (Phase 2)
Leukemia, Hairy Cell (Phase 2)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)
Leukemia, Myeloid (Phase 2)
Liver Neoplasms (Phase 2)
Trials (4 total)
Trial APIs (5 total)